Navigation Links
Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
Date:2/23/2011

DEERFIELD, Ill. and OSAKA, Japan, February 23, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone (CLD) for the treatment of hypertension, or high blood pressure. Discovered by Takeda, azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. Chlorthalidone is a long-acting oral thiazide-like diuretic used in the treatment of hypertension. The NDA submission was supported by four phase 3 clinical trials involving more than 4,000 patients with hypertension.

“Millions of patients with hypertension do not have their condition under control,” said Darryl Sleep, M.D., vice president, clinical science, Takeda Global Research & Development Center, Inc. U.S. “We believe this compound, the first in the U.S. to combine an ARB with chlorthalidone, could potentially provide an important new treatment option for patients with hypertension and the health care providers who manage them.”

In a phase 3 clinical trial, azilsartan medoxomil (20 mg/day, 40 mg/day and 80 mg/day), combined in a fixed-dose with CLD (12.5 mg/day and 25 mg/day), was studied versus azilsartan medoxomil and CLD monotherapies. In other studies, the fixed-dose combination of azilsartan medoxomil plus CLD was compared to azilsartan medoxomil coadministered with hydrochlorothiazide (HCTZ), another diuretic, and with a fixed-dose combination of olmesartan medoxomil and HCTZ.

Results from a phase 3 clinical trial of the fixed-dose combination of azilsartan medoxomil plus CLD were previously presented at the American Society of Hypertension, Inc. (ASH), 25th Annual Scientific Meeting and Exposition in New York in May 2010. The 10-week, randomized, double-blind study compared the effect of CLD and HCTZ, both in combination with azilsartan medoxomil, on systolic and diastolic blood pressure (SBP, DBP) by clinic blood pressure measurement and by ambulatory blood pressure monitoring (ABPM) in 609 patients with hypertension.

About HypertensionHypertension, or high blood pressure, is a chronic medical condition in which blood pressure is elevated at levels of 140 mm Hg or greater systolic or 90 mm Hg or greater diastolic. Hypertension impacts approximately 75 million Americans, or nearly one in three adults. It is estimated that nearly one billion people are affected by hypertension worldwide, and this figure is predicted to increase to 1.5 billion by 2025. Hypertension typically has no symptoms. Adults of all ages and backgrounds can develop hypertension; however, the risk of developing the condition increases with age, with more than half of people over age 60 affected. Hypertension is also costly to the nation’s health care system. The American Heart Association recently estimated that direct and indirect expenses associated with hypertension cost the nation more than $73 billion in 2009.

About Fixed-Dose Combination of Azilsartan Medoxomil Plus ChlorthalidoneDeveloped by Takeda, azilsartan medoxomil plus chlorthalidone is an investigational fixed-dose combination for the treatment of hypertension, or high blood pressure. The fixed-dose combination of azilsartan medoxomil plus chlorthalidone contains two medications, azilsartan medoxomil, an angiotensin II receptor blocker, and chlorthalidone, a long-acting thiazide-like diuretic used in the treatment of hypertension. The most commonly reported adverse drug reactions occurring in at least two percent of azilsartan medoxomil plus CLD-treated patients at the recommended doses and greater than azilsartan medoxomil or chlorthalidone monotherapies were increased blood creatinine (11%), dizziness (8.2%), blood uric acid (3.8%), blood urea (2.8%), and fatigue (2.5%). Most elevations of creatinine were transient and were generally associated with large blood pressure reductions.

About Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, gastroenterology, neurology and other conditions. To learn more about these Takeda companies, visit www.tpna.com.

About Takeda Pharmaceutical Company LimitedLocated in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com. Contacts: Josephine Zammuto

Takeda Global Research & Development

224-554-2795

josephine.zammuto@tpna.com

Elissa J. Johnsen

Takeda Pharmaceuticals North America

224-554-3185

ejohnsen@tpna.comCorporate Communications Dept.

Takeda Pharmaceutical Company Limited

+81-3-3278-2037
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc., U.S.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
2. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
3. Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
4. Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to Keep Enjoying Lifes Simple Pleasures
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Takeda Responds to FDA Advisory Committee Recommendation
7. Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
8. CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
9. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
10. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
11. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  According to the Centers for Disease Control and Prevention ... . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the month. ... health insurance regulations. ... to get a flu shot is by the end of October, according ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
Breaking Medicine News(10 mins):